NCT01897610View on ClinicalTrials.gov

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2017

Study Completion Date

July 4, 2017

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Immuncell-LC

intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour

Trial Locations (4)

400-711

Inha University Hospital, Incheon

120-752

Yonsei University Health System, Seoul

136-750

Korea University Anam Hospital, Seoul

137-701

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY